RxDoctor Payments Data

Lauren Fleps

Nurse Practitioner · Naperville, ILNPI 1720210107

Payments from drug & device makers

$3,588in general payments, 2019–2025

Across 123 payments — averaging $29.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$876
  • Novartis$488
  • AstraZeneca$460
  • Abbott$327
  • Actelion Pharmaceuticals US, Inc.$265
  • Bayer$263
  • plus $909 from 10 others

What the payments were for

  • Food & beverage$3,31392%
  • Education$2758%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,588 in reported general payments places this provider in the 90th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$80,460
Medicare patients
110
Services billed
761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag25$568,596
OpsumitMacitentan11$129,952
Orenitram ErTreprostinil Diolamine30$118,801
EntrestoSacubitril/Valsartan89$96,582
JardianceEmpagliflozin67$65,286
FarxigaDapagliflozin Propanediol39$33,384
EliquisApixaban24$18,822
Torsemide129$3,919
Bumetanide45$2,842
Eplerenone32$2,168
Isosorbide Dinitrate23$1,870
Spironolactone134$1,399
Potassium Chloride82$1,268
Metoprolol Succinate62$1,067
Midodrine Hcl26$974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$265$698,54736 claims
NovartisEntresto$488$96,58289 claims
Boehringer IngelheimJardiance$178$65,28667 claims
AstraZenecaFarxiga$460$33,38439 claims
PfizerEliquis$43$18,82224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →